Literature DB >> 28032341

NLRP3 inflammasome mediates interleukin-1β production in immune cells in response to Acinetobacter baumannii and contributes to pulmonary inflammation in mice.

Min-Jung Kang1, Sung-Gang Jo1, Dong-Jae Kim2, Jong-Hwan Park1.   

Abstract

Acinetobacter baumannii is a multi-drug resistant, Gram-negative bacteria and infection with this organism is one of the major causes of mortality in intensive care units. Inflammasomes are multiprotein oligomers that include caspase-1, and their activation is required for maturation of interleukin-1β (IL-1β). Inflammasome signalling is involved in host defences against various microbial infections, but the precise mechanism by which A. baumannii activates inflammasomes and the roles of relevant signals in host defence against pulmonary A. baumannii infection are unknown. Our results showed that NLRP3, ASC and caspase-1, but not NLRC4, are required for A. baumannii-induced production of IL-1β in macrophages. An inhibitor assay revealed that various pathways, including P2X7R, K+ efflux, reactive oxygen species production and release of cathepsins, are involved in IL-1β production in macrophages in response to A. baumannii. Interleukin-1β production in bronchoalveolar lavage (BAL) fluid was impaired in NLRP3-deficient and caspase-1/11-deficient mice infected with A. baumannii, compared with that in wild-type (WT) mice. However, the bacterial loads in BAL fluid and lungs were comparable between WT and NLRP3-deficient or caspase-1/11-deficient mice. The severity of lung pathology was reduced in NLRP3- deficient, caspase-1/11- deficient and IL-1-receptor-deficient mice, although the recruitment of immune cells and production of inflammatory cytokines and chemokines were not altered in these mice. These findings indicate that A. baumannii leads to the activation of NLRP3 inflammasome, which mediates IL-1β production and lung pathology.
© 2016 John Wiley & Sons Ltd.

Entities:  

Keywords:  Acinetobacter baumannii; NLRP3 inflammasome; interleukin-1β; macrophages

Mesh:

Substances:

Year:  2017        PMID: 28032341      PMCID: PMC5343352          DOI: 10.1111/imm.12704

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  41 in total

Review 1.  Mechanisms and functions of inflammasomes.

Authors:  Mohamed Lamkanfi; Vishva M Dixit
Journal:  Cell       Date:  2014-05-22       Impact factor: 41.582

2.  Activation of NLRP3 and AIM2 inflammasomes by Porphyromonas gingivalis infection.

Authors:  Eunjoo Park; Hee Sam Na; Yu-Ri Song; Seong Yeol Shin; You-Me Kim; Jin Chung
Journal:  Infect Immun       Date:  2013-10-14       Impact factor: 3.441

3.  K⁺ efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter.

Authors:  Raúl Muñoz-Planillo; Peter Kuffa; Giovanny Martínez-Colón; Brenna L Smith; Thekkelnaycke M Rajendiran; Gabriel Núñez
Journal:  Immunity       Date:  2013-06-27       Impact factor: 31.745

4.  Cytosolic flagellin requires Ipaf for activation of caspase-1 and interleukin 1beta in salmonella-infected macrophages.

Authors:  Luigi Franchi; Amal Amer; Mathilde Body-Malapel; Thirumala-Devi Kanneganti; Nesrin Ozören; Rajesh Jagirdar; Naohiro Inohara; Peter Vandenabeele; John Bertin; Anthony Coyle; Ethan P Grant; Gabriel Núñez
Journal:  Nat Immunol       Date:  2006-04-30       Impact factor: 25.606

5.  Acinetobacter baumannii outer membrane protein A induces dendritic cell death through mitochondrial targeting.

Authors:  Jun Sik Lee; Chul Hee Choi; Jung Wook Kim; Je Chul Lee
Journal:  J Microbiol       Date:  2010-06-23       Impact factor: 3.422

6.  Inflammation and fibrosis during Chlamydia pneumoniae infection is regulated by IL-1 and the NLRP3/ASC inflammasome.

Authors:  Xianbao He; Samrawit Mekasha; Nikolaos Mavrogiorgos; Katherine A Fitzgerald; Egil Lien; Robin R Ingalls
Journal:  J Immunol       Date:  2010-04-14       Impact factor: 5.422

Review 7.  Inflammasome activation and IL-1β and IL-18 processing during infection.

Authors:  Frank L van de Veerdonk; Mihai G Netea; Charles A Dinarello; Leo A B Joosten
Journal:  Trends Immunol       Date:  2011-02-18       Impact factor: 16.687

8.  Neutrophil IL-1β processing induced by pneumolysin is mediated by the NLRP3/ASC inflammasome and caspase-1 activation and is dependent on K+ efflux.

Authors:  Mausita Karmakar; Michael Katsnelson; Hesham A Malak; Neil G Greene; Scott J Howell; Amy G Hise; Andrew Camilli; Aras Kadioglu; George R Dubyak; Eric Pearlman
Journal:  J Immunol       Date:  2015-01-21       Impact factor: 5.422

9.  Multidrug-resistant Acinetobacter baumannii Harboring OXA-24 carbapenemase, Spain.

Authors:  Joshi Acosta; Maria Merino; Esther Viedma; Margarita Poza; Francisca Sanz; Joaquín R Otero; Fernando Chaves; Germán Bou
Journal:  Emerg Infect Dis       Date:  2011-06       Impact factor: 6.883

10.  Evidence for a gamma-interferon receptor that regulates macrophage tumoricidal activity.

Authors:  A Celada; P W Gray; E Rinderknecht; R D Schreiber
Journal:  J Exp Med       Date:  1984-07-01       Impact factor: 14.307

View more
  23 in total

Review 1.  Crosstalk between ER stress, NLRP3 inflammasome, and inflammation.

Authors:  Wei Li; Ting Cao; Chunyi Luo; Jialun Cai; Xiangping Zhou; Xinhua Xiao; Shuangquan Liu
Journal:  Appl Microbiol Biotechnol       Date:  2020-05-24       Impact factor: 4.813

2.  Schwann cell transplantation exerts neuroprotective roles in rat model of spinal cord injury by combating inflammasome activation and improving motor recovery and remyelination.

Authors:  Mahboubeh Mousavi; Azim Hedayatpour; Keywan Mortezaee; Yousef Mohamadi; Farid Abolhassani; Gholamreza Hassanzadeh
Journal:  Metab Brain Dis       Date:  2019-06-04       Impact factor: 3.584

Review 3.  Molecular mechanisms and functions of pyroptosis, inflammatory caspases and inflammasomes in infectious diseases.

Authors:  Si Ming Man; Rajendra Karki; Thirumala-Devi Kanneganti
Journal:  Immunol Rev       Date:  2017-05       Impact factor: 12.988

4.  Type I IFN operates pyroptosis and necroptosis during multidrug-resistant A. baumannii infection.

Authors:  Yang Li; Xiaomin Guo; Chunmiao Hu; Yan Du; Chuansheng Guo; Weiheng Zhao; Gonghua Huang; Chunliang Li; Qiumin Lu; Ren Lai; Tao Xu; Xiaopeng Qi
Journal:  Cell Death Differ       Date:  2018-01-19       Impact factor: 15.828

Review 5.  Innate Immune Responses to Acinetobacter baumannii in the Airway.

Authors:  Sílvia Pires; Dane Parker
Journal:  J Interferon Cytokine Res       Date:  2019-04-23       Impact factor: 2.607

6.  USP5 attenuates NLRP3 inflammasome activation by promoting autophagic degradation of NLRP3.

Authors:  Baoshan Cai; Jian Zhao; Yuling Zhang; Yaxing Liu; Chunhong Ma; Fan Yi; Yi Zheng; Lei Zhang; Tian Chen; Huiqing Liu; Bingyu Liu; Chengjiang Gao
Journal:  Autophagy       Date:  2021-09-05       Impact factor: 13.391

7.  USP19 suppresses inflammation and promotes M2-like macrophage polarization by manipulating NLRP3 function via autophagy.

Authors:  Tao Liu; Liqiu Wang; Puping Liang; Xiaojuan Wang; Yukun Liu; Jing Cai; Yuanchu She; Dan Wang; Zhi Wang; Zhiyong Guo; Samuel Bates; Xiaojun Xia; Junjiu Huang; Jun Cui
Journal:  Cell Mol Immunol       Date:  2020-10-23       Impact factor: 22.096

8.  IL-1β Production by Intermediate Monocytes Is Associated with Immunopathology in Cutaneous Leishmaniasis.

Authors:  Daniela Santos; Taís M Campos; Maíra Saldanha; Sergio C Oliveira; Mauricio Nascimento; Dario S Zamboni; Paulo R Machado; Sérgio Arruda; Phillip Scott; Edgar M Carvalho; Lucas P Carvalho
Journal:  J Invest Dermatol       Date:  2017-12-12       Impact factor: 8.551

9.  Caspase-11 Plays a Protective Role in Pulmonary Acinetobacter baumannii Infection.

Authors:  Wei Wang; Yue Shao; Shengjun Li; Na Xin; Tingxian Ma; Chenghai Zhao; Min Song
Journal:  Infect Immun       Date:  2017-09-20       Impact factor: 3.441

10.  [Mechanism and material basis of Lianhua Qingwen capsule for improving clinical cure rate of COVID-19: a study based on network pharmacology and molecular docking technology].

Authors:  Haiyan Yan; Chuncai Zou
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2021-01-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.